Table 1.
Clinicopathological characteristics of upper tract urothelial carcinoma patients who underwent radical nephroureterectomy.
| Patient characteristics | Patients who underwent RNU | Total n = 214, (%) |
|---|---|---|
| Follow‐up duration | Mean ± SD | 62.7 ± 39.2 |
| Time to death | Mean ± SD | 57.9 ± 42.3 |
| Time to metastasis | Mean ± SD | 39.1 ± 43.6 |
| Time to bladder tumor recurrence | Mean ± SD | 20.0 ± 7.87 |
| Age | < 75 | 107 (50.0) |
| ≥ 75 | 107 (50.0) | |
| Sex | Male | 158 (73.8) |
| Female | 56 (26.2) | |
| Tumor location | Pelvis | 105 (49.1) |
| Ureter | 109 (50.9) | |
| Tumor histology | Pure UC | 172 (80.4) |
| Non‐pure UC | 42 (19.6) | |
| Pathological T stage | < 3 | 98 (45.8) |
| ≥ 3 | 116 (54.2) | |
| Pathological N stage | 0 | 199 (93.0) |
| 1,2 | 15 (7.0) | |
| Lymph node dissection | No | 150 (70.1) |
| Yes | 64 (29.9) | |
| Surgical margin | Negative | 189 (88.3) |
| Positive | 25 (11.7) | |
| Tumor grade | Low | 64 (29.9) |
| High | 150 (70.1) | |
| LVI | Absent | 118 (55.1) |
| Present | 96 (44.9) | |
| Concomitant CIS | No | 170 (79.4) |
| Yes | 44 (20.6) | |
| Tumor multifocality | No | 182 (85.0) |
| Yes | 32 (15.0) | |
| Systemic adjuvant chemotherapy | No | 140 (65.4) |
| Yes | 74 (34.6) | |
| Previous history of bladder cancer | No | 149 (69.6) |
| Yes | 65 (30.4) |
CIS, carcinoma in situ; LVI, lymphovascular invasion; RNU, radical nephroureterectomy; SD, standard deviation; UC, urothelial carcinoma.